Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - Aegerion Pharmaceuticals, Inc. | a16-16151_1ex99d1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 8, 2016
AEGERION PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
001-34921 |
|
20-2960116 |
|
(State or other jurisdiction |
|
(Commission |
|
(IRS Identification No.) |
One Main Street, Suite 800
Cambridge, MA 02142
(Address of principal executive offices)
Registrant’s telephone number, including area code: (617) 500-7867
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨ |
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
|
¨ |
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b) |
|
|
|
|
¨ |
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01. Other Events.
Updated Risk Factors and Legal Proceedings
Aegerion Pharmaceuticals, Inc. is filing the risk factors and legal proceedings attached hereto as Exhibit 99.1 for the purpose of updating the risk factor and legal proceedings disclosure contained in its prior public filings, including those discussed under the caption “Risk Factors” and “Legal Proceedings,” respectively, in its Annual Report on Form 10-K for the year ended December 31, 2015, which was filed with the Securities and Exchange Commission (the “SEC”) on March 15, 2016, and its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2016, which was filed with the SEC on May 16, 2016.
Item 9.01. Financial Statements and Exhibits.
|
(d) |
Exhibits. |
|
Exhibit No. |
|
Description |
|
99.1 |
|
Risk Factors and Legal Proceedings |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: August 8, 2016
|
|
AEGERION PHARMACEUTICALS, INC. | |
|
|
| |
|
|
|
|
|
|
By: |
/s/ Benjamin Harshbarger |
|
|
|
Benjamin Harshbarger |
|
|
|
Acting General Counsel |